Drug Trial Radar · NCT07628985
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
374
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Carnot LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer are: Does Bofanglutide (GZR18) provide glycemic control comparable to Semaglutide based on changes in HbA1c? Is Bofanglutide (GZR18) safe and well tolerated in the study population? Can participants achieve glycemic targets and improve metabolic outcomes during treatment? Researchers will compare participants receiving Bofanglutide (GZR18) with participants receiving Semaglutide to evaluate their effects on glycemic control, metabolic outcomes, safety, quality of life, and treatment satisfaction. Participants will: Be randomly assigned in a 1:1 ratio to receive Bofanglutide (GZR18) or Semaglutide. Continue stable metformin monotherapy during the study. Receive subcutaneous study treatment with dose escalation according to the study protocol. Participate in 30 weeks of active treatment. Attend scheduled study visits, laboratory assessments, and safety evaluations. Complete questionnaires related to quality of life and treatment satisfaction.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
BofanglutideBiological
Long-acting GLP-1 receptor agonist administered as a subcutaneous injection every two weeks with dose escalation from 1.5 mg up to 18 mg according to the study protocol.
SemaglutideBiological
GLP-1 receptor agonist administered as a weekly subcutaneous injection with dose escalation from 0.25 mg up to 1 mg according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30Time frame: Baseline to Week 30
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran
Mexico City, Mexico
Private Practice
Mexico City, Cuauhtémoc, Mexico
Asociación Mexicana para la Investigación Clínica A.C. AMIC
Pachuca, Hidalgo, Mexico
Instituto Jalisciense de Investigación en Diabetes y Obesidad, S.C.
Guadalajara, Jalisco, Mexico
Arechavaleta Granell Maria del Rosario Consultorio de Medicina Especializada
Guadalajara, Jalisco, Mexico
Universidad Autónoma de Nuevo Leon. Facultad de Medicina
Monterrey, Nuevo León, Mexico
Oaxaca Site Management Organization, S.C.
Oaxaca City, Oaxaca, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.